ECASS health economic feasibility study. Report. ScHARR HEDS Discussion Papers by [email protected] | Oct 30, 2023
Cost-effectiveness of pembrolizumab for first-line treatment in patients with persistent, recurrent, or metastatic cervical cancer in the United States by [email protected] | Oct 30, 2023
Cost-effectiveness of Rotavirus Vaccination in the Netherlands – A disease transmission dynamic modelling approach by [email protected] | Oct 20, 2023
